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Abstract— Throughout the years, the palliative treatment of 
bone metastases using bone seeking radiotracers has been part of 
the therapeutic resources used in oncology. However, the choice of 
which bone seeking agent to use is not consensual. Computer 
simulation is a simple and practical solution to study and to 
compare a variety of radioisotopes. This study aimed to compare 
11 different radioisotopes currently in use or under research. 
Hence, computational models were used to estimate the 
percentage of deoxyribonucleic acid damage, the probability of 
correct DNA repair, and the radiation-induced cellular effects 
post-irradiation. 223Ra alpha particles, 177Lu beta minus particles, 
and 170Tm beta minus particles induced the highest cell death of 
all investigated particles and radioisotopes. The cell survival 
fraction measured post-irradiation with beta minus particles 
emitted by 89Sr and 153Sm, was higher than 177Lu beta minus 
particles and 223Ra alpha particles. Findings reported here may 
prompt future in vitro and in vivo experiments comparing 
different radionuclides for palliative treatment of bone 
metastases. 
Index Terms—computational methdos; deoxyribonucleic acid; 
Radium-223; Lutetium-177 
I.  INTRODUCTION  
Cancer is a major public health concern, and it is associated 
with significant morbidity and mortality. In 2012, 
approximately 14 million new cases were diagnosed, and 8 
million cancer-related deaths occurred. Prostate cancer is the 
second most common cancer in men worldwide [1]. A large 
percentage of patients with prostate cancer (65-75%) develop 
bone metastasis[2]–[4], which often leads to severe pain, 
hypercalcemia, lack of mobility and depression that adversely 
affect these patients’ life quality [5]. There are several 
therapeutic approaches targeting bone metastases and its 
associated effects, including the use of analgesics, external 
beam radiotherapy and radionuclide systemic therapy. The 
latter, systemic palliative targeted-therapy with suitable 
radiotracers, has emerged as a particularly appealing and 
efficient treatment modality for patients with multiple skeletal 
metastases [3], [6]–[8]. 
Over the years, efforts were made to identify radionuclides 
with improved physical properties for use in palliative care of 
metastatic bone pain. A major challenge associated with the 
palliative treatment of bone pain using selective radiotracers is 
to deliver an adequate dose of ionizing radiation to the bone 
lesion, while minimizing the dose to healthy bone sites and 
adjacent tissues. The radionuclide emitted particles should have 
an energy and tissue penetration range compatible with the 
volume of the lesion to be irradiated [2], [9], given that both 
the energy and the penetrating range of a radionuclide emitted 
particle significantly contribute to the therapy efficacy [10]. 
Therefore, studying the effects of particulate radiation at the 
cellular level is of interest to determine the suitability of a 
given radionuclide for target-tumor radiotherapy. There are 
essentially three main types of radioactive particles that are of 
interest for target-tumor radiotherapy: beta minus (β-) particles, 
alpha (α) particles and Auger electrons. In addition to the 
physical properties of different radionuclides for target-tumor 
therapy, other characteristics should be taken into consideration 
while searching for the ideal radiotracer for palliative treatment 
of bone metastases. For example, the radionuclide production 
costs and feasibility should be determined, and consideration 
should be given on whether its properties are amenable for 
radiochemistry procedures [8]. 
32P was the first radioisotope to be evaluated for palliative 
treatment of bone metastases and its first clinical use dates 
back to 1941 [11]. Presently, one of the most commonly used 
radionuclides for palliative treatment of bone metastases in 
routine clinical practice is 153Sm, which was approved by the 
Food and Drug Administration (FDA) for clinical use in 1997 
[12]. 89Sr is also currently used in the clinical setting for 
alleviation of bone pain and it was approved by the FDA for 
clinical use in 1993 [13]. Recently, a significant amount of 
work has been carried out using 223Ra, a promising therapeutic 
agent for palliative treatment of bone metastases, in order to 
take advantage of the low tissue penetration range associated 
with its emitted α particles. Its clinical use was approved by the 
FDA in 2013 [14]. Another promising radionuclide recently 
proposed for palliative treatment of bone metastasis was 177Lu, 
due to its appealing physical characteristics; in particular, its 
half-life of 6.73 days, gamma ray emission of 113keV (6.4%) 
and 208 keV (10.4%) and tissue penetration of 1.8 mm [13].  
Despite the increasing availability of radionuclides for 
palliative treatment of bone metastases [13], [15], the choice of 
which therapeutic agent to use is not consensual across sites 
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and no standardization or guideline exists to assist with this 
choice. This may be due to the limited data available 
concerning the advantages and disadvantages of each 
radioisotope, as well as assessing all radioisotopes in the same 
test conditions. Computational simulation is a simple and 
practical method to study and to compare a variety of 
radioisotopes for different medical applications, including the 
palliative treatment of bone metastases, under the same 
research conditions [16]. This study aimed to use 
computational methods to compare different radioisotopes 
currently in use or under research for the palliative treatment of 
bone metastases. In particular, the work developed is focused 
on the bone metastases from the prostate carcinoma, given this 
is one of the most common types of cancer in men worldwide, 
and the majority of these patients develop bone metastases. 
II. METHODS 
Three different computational simulators were used to 
investigate the therapeutic potential of the following 
radioisotopes: 32P, 89Sr, 90Y, 117mSn, 153Sm, 166Ho, 170Tm, 
177Lu, 186Re, 188Re and 223Ra. The sections below explain the 
main principles of these simulators and point out the key 
input parameters adopted. 
A. Monte Carlo damage simulator 
The Monte Carlo damage simulation (MCDS) algorithm 
can be used to predict the types of deoxyribonucleic acid 
(DNA) damage and their yield after irradiation. This method 
allows for rapid collection of a large data set with multiple 
irradiation scenarios. The model generates a number of 
damage configurations expected within the DNA of one cell, 
where the algorithm processes information in two main steps: 
first, it randomly distributes, in a DNA segment, the expected 
amount of damage produced in a cell; then, it subdivides the 
distribution of damage in that particular DNA segment. A 
detailed description of the MCDS model as well as additional 
discussions about the validity and limitations this method are 
presented in [17] and [18]. 
The classification scheme used by the MCDS to 
categorize DNA damages is based on the classification 
parameters proposed by Nikjoo et al., for further details, see 
[19] and [20]. 
B. Monte carlo excision repair simulator 
The Monte Carlo excision repair (MCER) algorithm can be 
used to calculate the formation and repair of DNA damages 
and to predict repair outcomes such as correct repair, repair 
with a mutation and conversion into a DSB [21]. The MCER 
algorithm starts by using the MCDS algorithm to generate a 
random number of damage configurations expected within the 
DNA of one cell. Subsequently, the MCDS-generated damage 
configurations are superimposed over a predetermined 
nucleotide sequence or a random nucleotide sequence. Then, 
the MCER model is used to simulate the repair, misrepair and 
aborted excision repair of damage within the entire genome or 
within a specific region of the DNA. The lesions forming a 
cluster are removed sequentially through repeated rounds of 
excision repair. 
The majority of DNA oxidative damage, including 
modified apurinic/apyrimidinic converted into strand breaks, 
requires repair by base excision repair (BER). Two different 
types of BER processes have been observed in eukaryotic and 
prokaryotic cells: (1) e xcision and replacement of a single 
nucleotide, known as short-patch BER (SP-BER), which 
occurs in most cases; and (2) replacement of 2–13 
nucleotides, known as long-patch BER (LP-BER). Another 
enzymatically distinct repair pathway is nucleotide excision 
repair (NER). The NER, observed in eukaryotic cells, 
substitutes oligonucleotide fragments of 24–32 nucleotides in 
length [21]. Results from this simulator are outputted as 
simplified repair scenarios, due to the current uncertainties 
associated with the processing of radiation-induced damage by 
the BER and NER pathways. The studies by Semenenko and 
Stewart have demonstrated that the results obtained by this 
simulator correlate well with in vitro results obtained using 
cell cultures [22]. A detailed description of the MCER 
algorithm, as well as additional discussions on the validity and 
limitations of the model can be found in [17] and [21]. 
C. Virtual Cell radiobiology simulator 
The radiation-induced damage can be lethal or can be 
slowly repaired via enzymatic repair and misrepair, which then 
determines the fate of the irradiated cell. The cell cycle 
kinetics can influence and/or be influenced by the kinetics of 
damage processing; and damages to the DNA are often a 
trigger for apoptosis, although cell membrane damages can 
also induce apoptosis [21], [23]. Radiobiological models have 
been developed to describe the dose-response association, the 
process of damage production and the key repair mechanisms. 
These models often correlate the dose rate with the cell 
response to irradiation.  
Further details on this computational simulator can be 
found at: http://faculty.washington.edu/trawets/vc.  
D. Simulated parameters 
For each investigated radioisotope, only the most 
abundantly emitted radioactive particles were evaluated using 
the MCDS and MCER simulators. The general input details 
used for simulations with the MCDS model were as follows: 
initial cell number of 1000 and DMSO concentration of 0. The 
MCER input conditions are defined as: inhibition distance of 3 
base pairs; probability of choosing a lesion from the first stand 
break of 0.5; polymerase error rate for SP-BER and LP-BER of 
1.0-4 and 1.0-6, respectively; probability of incorrect insertion of 
opposite base lost of 0.75; and probability of incorrect insertion 
of opposite damaged base of 0.75.  
In the input file for the VC simulator, the cell cycle time 
(Tc) and the cell potential doubling time (Tpot) values were 
adjusted to modeling two different cell phenotypes: normal 
prostate cells (Tc = 48 h and Tpot = 500 days) and metastatic 
prostate cells (Tc = 48 h and Tpot = 54 days) [24]. The 
number of DSBs and the percentage of complex DSBs were 
obtained from the MCDS simulator. These results were then 
applied as input parameters for the TLK model used in the VC 
simulator. Irradiation periods of 2, 24, 48, 120 and 240 h 
(TCUT – time allowed for repair after exposure), with total 
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absorbed doses of 0 .1, 0.5, 1, 2, 5 and 8 Gy were studied 
using t h e  V C  simulator. Other parameters used in the VC 
simulator, specified in the TLK model input file, included: (1) 
DRM (damage repair model) = TLK, (2) CKM (cell kinetics 
model) = QECK (quasi-exponential cell kinetics model); (3) 
DNA (cell DNA content) = 5.667D+09 base pair; (4) DSB 
(endogenous) = 4.3349×10-03 Gy-1 cell-1; (5) RHT (repair half-
time) = XXX, XXX = 0.25, 9 h (simple DSBs are repaired 
faster than complex DSBs); (6) A0 (probability of correct 
repair) = AAA, AAA = 0.95, 0.25 (simple DSBs are repaired 
more accurately than complex DSBs); (7) ETA (pairwise 
damage interaction rate) = 2.5×10-04 h-1; (8) PHI (probability 
of a misrejoined DSB being lethal) = 0.005; (9) GAM 
(fraction of binary-misrepaired damages that are lethal) = 
0.25; (10) N0 (initial number of cells) = 1000; (11) KAP 
(peak cell density) = 1.0D+38 cells/cm3; (12) VOL (tissue 
volume) =  1 cm3; (13) FRDL (fraction of residual that is 
lethal damage) = 0.5; (14) ACUT (absolute residual damage 
cutoff) = 1.0E−09 expected number of DNA damages per cell; 
(15) BGDR (average background absorbed dose rate on 
planet Earth) = 2.73748×10-07 Gy/h; (16) DCUT (dose cutoff) 
= 0.01 Gy; (17) STOL (step-size tolerance) = 0.01 Gy/h; (18) 
SAD (scaled absorbed dose) = RX1, RX1 = 0.1, 0.5, 1, 2, 5 
and 8 Gy; (19) GF [growth fraction, if 0 (zero) all cells are 
quiescent, if 1 (one) all cells are cycling and if 0.5 the cell 
population is heterogeneous] = 0, 0.5, 1 [25]. 
III. RESULTS 
A. MCDS and MCER 
Fig 1 presents the radiation-induced DNA damages 
obtained post-irradiation with different radioactive particles, 
emitted by selected radioisotopes. The probability of correct 
repair, repair with a mutation and conversion into a DSB, and 
the number of repair cycles are presented in Fig 2. Results 
obtained using the MCDS and MCER algorithms showed that 
223Ra α particles were able to induce the highest amount of 
DNA damages of all investigated particles, having the 
lowest probability of correct repair of damages and highest 
probability of the repair processes to induce DSB. 
B. VC simulator 
The cell survival fraction results obtained after irradiation 
with different radionuclides and particles are shown in Fig 3. 
The estimated survival fraction rank order of all investigated 
particles was: 166Ho β- particles, 186Re β- particles, 188Re β- 
particles > 89Sr β- particles > 32P β- particles > 90Y β- 
particles > 117mSn electrons > 153Sm β- particles > 177Lu β- 
particles > 170Tm β- particles >> 223Ra α particles. 
Additionally, statistically significant differences were 
observed among the different irradiating agents (p < 0.0001 
and p = 0.0053 ANOVA, with and without 223Ra data, 
respectively). The 223Ra α particles, the 170Tm β- particles 
and the 177Lu β- particles had the lowest survival fraction of 
all investigated irradiating agents, as determined using the 
VC simulator. Detailed examination of the estimated 
number of surviving cells at different proliferation status 
for these 3 irradiating agents is presented in Figs. 4 and 5. 
The estimated number of normal prostate cells that 
survived irradiation when all cells were quiescent and when 
all cells were actively dividing is presented in Figs. 4a-4b, 
respectively. The number of metastatic prostate cells that 
survive the irradiation when all cells are quiescent and all cells 
are actively dividing is shown in Figs. 5a-5b, respectively. 
When all cells were quiescent, the estimated number of normal 
prostate surviving cells is similar to the estimated number of 
metastatic prostate cells that survive irradiation and seems to be 
independent from the cell kinetic (Figs. 4a and 5a). Conversely, 
for actively dividing cellular populations, it is possible to 
observe that there are fewer surviving cells in the normal 
prostate cell population than in the metastatic prostate cell 
population (Figs. 4b and 5b). The estimated number of cells 
that survived a given irradiation scenario decrease in the 
following order: 177Lu β- particles > 170Tm β- particles > 
223Ra α particles. Statistically significant differences were 
observed among these 3 different irradiating agents when 
normal prostate cells were quiescent and all cells were 
actively dividing (p < 0.0001, ANOVA). Similar results 
were found for the metastatic prostate cells (p < 0.0001, 
ANOVA).  
Figure 1.    DNA damage results obtained using the MCDS simulator. (A) Percentage of total DNA radioinduced SSB after irradiation; (B) Percentage of two 
different types of complex SSB; (C) Fraction of complex SSB DNA damages after irradiation; (D) Percentage of total DNA radioinduced DSB after irradiation; 
(E) Percentage of two different types of complex DSB, (F) Fraction of complex DSB DNA damages after irradiation.   
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IV. DISCUSSION AND CONCLUSION 
Here, different computational methods were used to 
evaluate multiple radioisotopes for the palliative treatment of 
bone metastases, specifically in the context of metastatic 
prostate tumors. In this analysis, radioisotopes currently used in 
the clinical practice or under research as potentially useful 
agents for treatment of palliative bone metastases were 
included. The biological effects resulting from irradiation with 
these radioisotopes, both at the DNA level and at the cellular 
level, were evaluated and compared. Our findings indicated 
that the most promising agents for palliative treatment of bone 
metastases from prostate cancer are the 223Ra α particles, the 
177Lu β- particles and the 170Tm β- particles. Other commonly 
used radioisotopes for palliative treatment of bone 
metastases, such as 89Sr, were found to be inferior in 
inducing lethal damages than 177Lu, 170Tm or 223Ra, with 
radiobiological properties similar to 32P. Overall data also 
suggested that 153Sm β- particles were superior at inducing 
cell death compared with 89Sr β- particles. 
The MCDS results showed that the percentage of SSB 
and DSB after irradiation were highest for 223Ra α particles, 
followed by 177Lu β- particles. The same trend was 
observed for a percentage of complex SSB and DSB. 
Conversely, the probability of correct repair was low for 
these irradiating agents and the number of repair cycles was 
high for all the repair processes studied, regardless of the 
repair route (MCER results). A higher number of repair cell 
cycles has been correlated with prolonged repair times [22], 
[25], which correlates with the increased percentage of 
complex damages. Previous studies have demonstrated that 
the complex damage repair by excision can lead to an 
increased number of DSBs [22], [26]. It is well known that 
DNA DSBs are frequently associated with apoptosis 
induction [18]. The damage induced by 223Ra α particles and 
177Lu β- particles seem to have hampered the successful 
repair of the DNA by BER or NER, presenting a high 
probability for DSB formation and low probability for 
correct repair. Furthermore, the high number of DNA DSBs 
induced by the 223Ra α particles and 177Lu β- particles 
together with their high DNA SSB conversion to DSB may 
translate an increased probability of apoptosis induction for 
these three radioisotopes compared with the other investigated 
agents. In fact, data from the VC simulator estimated a low 
survival fraction for 223Ra α particles and 177Lu β- particles, 
suggesting these irradiating agents would be more 
promising in the killing of metastatic cells than the other 
investigated irradiating agents. Furthermore, the VC 
simulator estimated a low survival fraction for cells 
irradiated with 170Tm β- particles. Interestingly, the total 
number of DSB induced by DNA irradiation with 170Tm β- 
particles was in the low range, but the percentage of 
complex DSB was ranked together with 177Lu β- particles, 
which supports for the importance of modeling the fraction 
of complex DSB when determining the radiation induced 
cell damages using radiobiological models. 
Detailed analysis of the cellular kinetics post-irradiation 
using 177Lu β-, 170Tm β- and 223Ra α particles showed that 
the cell response was dose- and radionuclide-dependent. 
For low dose TCUTs, virtually no differences were found 
between 170Tm β- and 177Lu β- particles. Conversely, for 
high TCUT values, irradiation with 170Tm β- particles 
resulted in a lower number of surviving cells than 
irradiation with 177Lu β- particles. This may be a result of 
differences in the physical half-life of 177Lu and 170Tm (6.2 
and 127.8 days, respectively) that will contribute 
differently for dissimilar radiation fractioning.  
The findings also showed that a larger number of 
metastatic cells survived irradiation when compared with 
normal prostatic cells, in particular, when all cells were 
actively dividing. This observation highlights the influence 
of cell proliferation rate on cell response to irradiation, 
where a faster cell cycle time means the cells were less 
radiosensitive. Due to its shorter doubling time (54 days 
versus 500 days for metastatic and normal cells, 
respectively), metastatic prostate cells were able to 
compensate radiation-induced damage by rapid cell 
duplication.  
223Ra α particle emission is an appealing strategy for the 
treatment of bone micrometastases, owing to the short 
tissue range penetration associated with these radioactive 
Figure 2.   DNA damage repair results obtained using the MCER simulator. 
Probability (A) of correct repair (p COR), (B) repair with mutation (p MUT), 
(C) conversion to DSB (p DSB) of DNA SSB and (D) average number of 
repair cycles. 




particles that can allow for a more circumscribed 
irradiation surface. Furthermore, typically α emitters induce 
less hematologic toxicity for a given bone surface dose than 
β- emitters. The high linear energy transfer of α particles 
has been associated with greater biological effectiveness 
than β- particles [6], [14], [27]. Our findings indicated that 
223Ra α particles induced significantly more DSBs and were 
more effective in inducing cell death than all the other 
particles.  
Within the β- particle emitters investigated here, 177Lu has 
the lowest tissue penetration range (1.8 mm). A common 
concern associated with the use of β- particle emitters is related 
to its large tissue penetration range of several millimeters, 
which can result in energy deposition in neighboring, non-
targeted cells, a phenomenon known as “crossfire” that may 
lead to bystander effects. With α particle emitters, due to their 
short tissue penetration range, the “crossfire” effect is not such 
a concern, but may require targeting virtually every cell within 
large size tumors and does not take advantage of the positive 
bystander effects [28]. The short tissue penetration range of 
177Lu β- particles is placed in the lowest end of the β- particle 
emitter’s tissue penetration range, minimizing the negative 
“crossfire” effects often associated with β- particle emitters; 
and it is higher than typical α particles allowing us to take 
advantage of the positive bystander effects that are not 
attainable with conventional α particles emitters. In addition, 
177Lu low β- particle energy and intermediate physical half-life 
of 6.73 days allow for a constant dose rate in the target lesion 
sites [29]. Here, we found that 177Lu β- particles induced the 
maximum number of DSB among all β- emitters studied 
radionuclides and was part of the top three most effective 
radionuclides to induce cell death. Data presented here together 
with the physical characteristics of 177Lu previously described, 
suggest that replacing the radionuclides 153Sm and 89Sr with 
177Lu in the EDTMP complex would improve the potential for 
cell death in target tissue, while reducing the bone marrow 
toxicity due to the shorter tissue penetration range of 177Lu β- 
particles in comparison with 153Sm and 89Sr β- particles. 
The long physical half-life of 170Tm (128.6 days) can be an 
advantage for this radiotracer distribution and storage 
compared with either 223Ra (11.4 days) or 177Lu (6.2 days) 
[12]. However, the physical half-life of a radioisotope and 
the dosing regimen adopted can have a considerable impact 
on cellular response to irradiation. For example, delivery of 
90% of the total dose of radiation requires approximately 
3.5 half-lives of decay, which will correspond to a time 
interval of approximately 64 weeks for 170Tm, 6 weeks for 
223Ra and 3 weeks for 177Lu [12]. This may explain the VC 
results presented here, where the number of cells surviving 
irradiation with 170Tm β- particles was lowest when the 
TCUT was highest. 
Computational methods allow for rapid and easy data 
collection. Nonetheless, some limitations have been pointed 
out, including modeling and evaluation based on current 
knowledge, which works as a mechanistic process. 
Furthermore, the computational algorithms used in this 
study only model simple repair processes and exclude 
DSBs repair processes, such as homologous repair and non-
homologous end joining (NHEJ) repair processes. 
Moreover, the used algorithms assume an optimal scenario 
of ionizing energy deposition directly into the DNA, 
scenario that often is challenging to achieve in vitro and in 
vivo due to inefficient radiotracer biodistribution processes. 
Therefore, these methods can be useful as a first-line approach 
to large data sets to help planning subsequent in vitro and in 
vivo studies, the data presented here requires further validation 
by means of in vitro and in vivo studies to fully establish the 
Figure 5.   Number of metastatic prostate cells that survive irradiation with 
different irradiating agents in a quiescent cell population (A), and in cells 
actively dividing (B). Simulated doses of 0.1, 0.5, 1, 2, 5 and 8 Gy and 
irradiation periods of 2, 24, 48, 120 and 240 h. 
Figure 1.   
Figure 4.   Number of normal prostate cells that survive irradiation with 
different irradiating agents in a quiescent cell population (A), and in cells 
actively dividing (B). Simulated doses of 0.1, 0.5, 1, 2, 5 and 8 Gy and 
irradiation periods of 2, 24, 48, 120 and 240 h. 
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therapeutic potential of the investigated radioisotopes in the 
context of palliative treatment of bone metastases. 
In conclusion, this study compared different irradiating 
agents using the same exposure conditions and controllable 
cell populations to clarify the quality of these radioisotopes 
for palliative treatment of bone metastases, specifically in the 
context of prostate cancer. Collected data allowed the ranking 
of eleven different radioisotopes in terms of ability to induce 
DNA damage and probability of damage repair. The top three 
agents able to induce the highest cellular damage and cell death 
were found to be the 177Lu β-, 170Tm β- and 223Ra α particles. 
223Ra-dichloride is a particularly appealing approach for the 
treatment of bone metastases based on the data reported 
here, this radionuclide physical properties, suitable 
production methods and feasible logistics of distribution. 
Within the β- particle emitters investigated, 177Lu was the 
preferred one due to its estimated low survival fraction, 
together with its adequate half-life and physical properties for 
image acquisition. Data presented here indicated that 89Sr and 
153Sm had modest effect on the cell survival fraction. Although 
in vitro and in vivo data are necessary to support our findings, 
the observations reported here may support for a careful 
rethinking of the widespread clinical use of 89Sr and 153Sm 
and, perhaps, strengthen the use of 223Ra and 177Lu in the 
palliative treatment of bone metastases. 
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